Soliton Inc. selected Greater Than One Group as the medical device company’s integrated marketing agency.
Eli Lilly and Company announced positive results from CENTURION, the company’s Phase III study looking into Reyvow (lasmiditan) for migraine attacks.
The U.S. Food and Drug Administration approved a new indication for GlaxoSmithKline plc and Innoviva Inc.’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to the product’s current license for use in patients with chronic obstructive pulmonary disease (COPD).
EVERSANA™ expands pharmaceutical training and digital engagement capabilities with acquisition of Alkemy Partners CHICAGO, Sept. 9, 2020 /PRNewswire/ — EVERSANA™, the leading provider of commercial services to the life science industry, today announced the acquisition of Alkemy Partners, a full-service field learning and development company committed to solving market access, sales and clinical engagement through training, […]
The U.S. Food and Drug Administration approved FoundationOne Liquid CDx, a new pan-tumor liquid biopsy test that is indicated for use as a companion diagnostic for four FDA-approved precision therapies.
German drugs and pesticides group Bayer will pay around $1.6 billion to settle the majority of U.S. claims involving the Essure birth-control device.
The U.S. House of Representatives approved a $3.2 billion budget proposal for the U.S. Food and Drug Administration that will boost the regulatory agency’s abilities to approve new medicines and medical devices, as well as protect the nation’s food supplies.
Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as non-alcoholic steatohepatitis (NASH), oncology and infectious diseases.
U.S. industrial conglomerate 3M Co. has partnered with the Massachusetts Institute of Technology to develop a rapid antigen test for COVID-19.
Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).